Investing in microcap biotech stocks may be a good way to increase your portfolio’s growth potential. There are many ways to do this, but first you need to decide which companies you’re interested in. Below are a few popular biotech companies that have been around for some time, and have the potential to experience growth in the near future.
Buying Actinium Pharmaceuticals stock at a low price is a great option for long-term investors. The company is developing a range of targeted radiotherapies that can attack cancer cells.
The company has several products in clinical trials, including its lead candidate, Iomab-B. This drug is being studied in patients with refractory or relapsed acute myeloid leukemia (AML). Iomab-B is a hematopoietic stem cell transplantation (HSCT) drug that has the ability to alleviate the adverse effects of CAR-T/Gene-Tx therapies.
Iomab-B is being studied in the phase 3 SIERRA trial, which assesses its safety in AML patients. The phase 3 trial is currently in progress and will continue through May 2020.
Actinium Pharmaceuticals has an industry-leading technology platform that can deliver radioisotopes directly to cells. This technology is part of Actinium’s AWE Technology platform. Using this technology, the company can target and kill multiple cancer targets, increasing the success of treatment.
The company is also in the process of developing a drug that has the ability to deplete the immune system, making it easier to treat cancer. This drug is based on Actinium-225, an isotope that is directed at several validated cancer targets.
The company also plans to release data from its late stage clinical trials by the end of this quarter. This could be a catalyst for another share price rally. In addition, Actinium has a strong management team and has already accrued a large amount of positive clinical data.
The company has cash and cash equivalents and anticipates having sufficient funds through mid-2025. In addition, Actinium has developed methods for producing the cancer treatment, AC-225. These methods can also be used for other treatments, including bone marrow transplants.
Founded on September 24, 1998, VolitionRX is a multi-national life sciences company. The company’s product line includes blood tests for epigenetic cancer detection, and hypergenomics tissue tests. VolitionRX is headquartered in Henderson, NV. The company’s fiscal year ends in October. VolitionRX has an impressive list of credentials, including independent auditors, a stellar board of directors and a plethora of high-ranking executives. The company has also recently announced its most recent financial results for the year ended December 31, 2021. VolitionRX has also recently signed an exclusive global supply and licensing agreement with Heska Corporation.
The company has also recently announced its most recent research and development initiatives. It has also hired the U.S.’s most high-profile oncology expert as its Chief Medical Officer. The company also has a subsidiary devoted to animal diagnostics.
In addition to its storied medical research and development activities, VolitionRX has a bevy of business development and product marketing initiatives. The company has also been a leader in the epigenetic cancer detection blood test market. In a recent industry survey, VolitionRX was cited as a leading player amongst the top players in this space. VolitionRX has also landed some high-profile research and development deals, including a collaboration with Salarius Pharmaceuticals, Inc. (NASDAQ: SARX) and a clinical study with Oncovet, a leading veterinary referral clinic. VolitionRX also has a bevy of other high-ranking executives, including the company’s president and CTO. VolitionRX is an exciting company with a lot of potential, especially for its clients. The company has a stellar track record of success, and is well-positioned to take advantage of the upcoming healthcare reform measures. VolitionRX’s most recent announcements are just the tip of the iceberg, and are likely to be followed by more in the coming months.
Located in Gaithersburg, Maryland, Novavax, Inc. develops vaccines for serious and emerging infectious diseases. These vaccines are designed to address global health needs.
Novavax’s COVID-19 vaccine candidate is based on a recombinant protein nanoparticle (RNP) technology. The protein is stable, and includes an adjuvant (Matrix-M). The company plans to manufacture 250 million doses per year.
Novavax has a collaboration agreement with Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical firm. Takeda will manufacture the COVID-19 vaccine candidate in Japan, and Novavax will receive a portion of the proceeds. The company also plans to expand production in the Czech Republic.
Novavax has been developing protein subunit vaccines for over 20 years. They use the protein of a targeted virus to activate the immune system. They also use an immune-boosting compound called an adjuvant. This type of vaccine is approved to prevent COVID-19 caused by the SARS-CoV-2 virus.
Novavax is undergoing clinical trials for its NVX-CoV2373 vaccine candidate, which is designed to protect against the SARS-CoV-2 virus. The company expects to produce 100 million doses of NVX-CoV2373 by late 2020. It will also launch a trial in the United States, enrolling 30,000 volunteers.
Novavax is undergoing clinical testing for its NVX-CoV2373 virus-like particle (VLP) vaccine candidate for the SARS-CoV-2 virus. It uses a baculovirus that has been infused with coronavirus spike proteins. The particles are studded with saponin and up to fourteen spike proteins. They are approximately 30 to 40 nanometers across. The vaccine was well tolerated.
The company is also partnering with the Serum Institute of India, a global vaccine manufacturer. The institute is producing billions of doses of vaccines for low- and middle-income countries, and is assisting Novavax in expanding its production in the Czech Republic.
Despite the lukewarm performance in the third quarter, Cassava microcap biotech stocks have been showing strong signs of recovery. The company announced positive results for clinical trials testing its simufilam drug in Alzheimer’s patients, and analysts have been bullish on its future.
Cassava’s progress is impressive, though the complexities of the company’s business model mean that some investors should keep their fingers crossed. This is particularly true for investors who are new to the biotech space.
Cassava’s ADAS-Cog-11 is a gold standard measure of cognition. This is not a new technology, but it’s not exactly the most accurate measurement.
Cassava’s stock has been on a tear lately, soaring over 145% on Monday. The company’s shares have traded over 4 million shares in the past week, and they are still trading above the 200-day moving average.
Cassava’s flagship drug candidate is simufilam, a blood-based biomarker that is intended to help detect Alzheimer’s disease. The company says that it has completed a Phase 2b clinical trial. It plans to start a Phase 3 trial in late 2021.
There are many reasons to be skeptical of Cassava. Its prominent clinical research site is co-owned by a former stripper and a crack addict. Its management has been accused of data manipulation, and the company’s approach to Alzheimer’s disease research has been under fire.
However, the company has managed to make a splash in the biotech space, and the company’s stock has jumped a good bit in the past month. Cassava’s stock price could rise by a moderate amount if the FDA approves its drug. The company also has the potential to make a multi-bagger if it does.
TG-1101) is a glycoengineered monoclonal antibody. It targets a unique epitope on the CD20 antigen and has shown clinical activity in patients with Rituxan-refractory disease. The antibody is approved in Israel for ulcerative colitis, and is being evaluated in relapsing-remitting forms of multiple sclerosis (MS).
Ublituximab was approved in Europe for B-cell lymphocytic leukemia. The company recently received Orphan Drug status for this disease in the US. It is expected to be approved for relapsing-remitting MS in the US next year. The drug is dosed less frequently than Ocrevus, and has a one-hour infusion time.
Ublituximab has improved effectiveness over the first-generation anti-CD20 molecules. The antibody targets 85% of MS diagnoses, and has consistently outstanding data in the MS space. In addition to MS, the antibody is also being evaluated in other autoimmune diseases.
Ublituximab is being evaluated in Phase 3 clinical trials for relapsing forms of MS. It is also being evaluated for patients with rheumatoid arthritis, psoriasis, and ulcerative colitis. The company has a $15M market cap.
A number of investors have been dumping biotech stocks over the past year. Many of these companies have seen their valuations drop by more than a third, while their shares have declined by more than 99% over the past five years. This has helped a number of microcap biotech names bend under their own setbacks.
The company is in the process of cutting more than 70% of its staff. It is also in the process of cutting its chief operating officer. This is likely to cause the company to lose a lot of investor capital.
Ublituximab may be competing with Roche’s Rozlytrek, Pfizer’s Xalkori, and Bristol Myers Squibb’s Turning Point Therapeutics. The company also has a promising macrolide antibiotic for community-acquired pneumonia.